Precision Medicine Is Critical for the Future of Oncology

Dr. Christian (Chris) Behrenbruch is the founder and chief executive officer of Telix Pharmaceuticals Ltd. (ASX.TLX, NASDAQ.TLX). He has over 25 y of commercial experience in nuclear medicine and radiology and has founded multiple companies in the field, including Mirada Medical, Adaptix, ImaginAb,

Authors

Institutions

Publication Details

Journal
Journal of Nuclear Medicine
Published
2025-08-14
DOI
https://doi.org/10.2967/jnumed.125.270966
Citations
1
Primary Topic
Cancer Genomics and Diagnostics
Type
article
Field-Weighted Citation Impact
0.94
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
article

Precision Medicine Is Critical for the Future of Oncology

Ken Herrmann, Johannes Czernin, Christian Behrenbruch
1 citations
Journal of Nuclear Medicine
Cancer Genomics and Diagnostics
0.94
article

Precision Medicine Is Critical for the Future of Oncology

Ken Herrmann, Johannes Czernin, Christian Behrenbruch
article en
1 citations

Abstract

Dr. Christian (Chris) Behrenbruch is the founder and chief executive officer of Telix Pharmaceuticals Ltd. (ASX.TLX, NASDAQ.TLX). He has over 25 y of commercial experience in nuclear medicine and radiology and has founded multiple companies in the field, including Mirada Medical, Adaptix, ImaginAb,

Journal of Nuclear MedicineVol. 66(9)
University of California, Los Angeles (US), Essen University Hospital (DE)
Openalex Percentile: Top 22%
Cancer Genomics and Diagnostics
0.94
DOIOpen Access PDFOpenAlex
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.